Masoudi Sahar, Hassanzadeh Nemati Amin, Fazli Hamid Reza, Beygi Samira, Moradzadeh Maliheh, Pourshams Akram, Mohamadkhani Ashraf
Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Middle East J Dig Dis. 2019 Jan;11(1):38-44. doi: 10.15171/mejdd.2018.126. Epub 2018 Oct 4.
BACKGROUND Aryl-carbon receptor (AhR), a ligand-activated transcription factor, is best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin. AhR is expressed in several tumor cells and regulates the expression of genes in the signal transduction pathways. In this study, we examined the soluble levels of AhR in patients with pancreatic cancer. METHODS 123 samples, including 59 (48%) samples of pancreatic ductal adenocarcinoma based on histological evidence and 64 (52%) healthy control samples, were evaluated to determine plasma levels of AhR by Enzyme-linked immunoassay. RESULTS The median of AhR among patients was 0.280 ng/mL, which differed considerably from 0.07 ng/mL in the control group ( < 0.001). Significant differences of the AhR were observed between the plasma samples of the patients compared with the healthy group, with respect to male sex ( < 0.001), age groups ( = 0.001), diabetic status ( < 0.001), body mass index (BMI) categories ( = 0.035), and constantly smokers ( < 0.001). We also observed significant differences between the level of AhR expression between men and women ( = 0.01) and ever to never smokers ( = 0.009) in the case group. In addition, the age of 65 and a BMI of 25 or less were significant factors in plasma AhR levels ([1.61 95%CI 1.08-2.38] and [1.84 95%CI 1.22-2.77], respectively). CONCLUSION The results of this study can add diagnostic information to pancreatic cancer involving AhR and the potential efficacy of this receptor in therapeutic strategies.
背景 芳基碳受体（AhR）是一种配体激活的转录因子，以其介导环境毒素（如2,3,7,8-四氯二苯并对二恶英）作用的能力而闻名。AhR在多种肿瘤细胞中表达，并调节信号转导通路中基因的表达。在本研究中，我们检测了胰腺癌患者中AhR的可溶性水平。方法 对123份样本进行评估，其中包括59份（48%）基于组织学证据的胰腺导管腺癌样本和64份（52%）健康对照样本，通过酶联免疫吸附测定法测定血浆中AhR的水平。结果 患者中AhR的中位数为0.280 ng/mL，与对照组的0.07 ng/mL有显著差异（<0.001）。与健康组相比，患者血浆样本中的AhR在男性（<0.001）、年龄组（=0.001）、糖尿病状态（<0.001）、体重指数（BMI）类别（=0.035）和持续吸烟者（<0.001）方面存在显著差异。我们还观察到病例组中男性和女性之间（=0.01）以及曾经吸烟者和从不吸烟者之间（=0.009）AhR表达水平存在显著差异。此外，65岁的年龄和25或更低的BMI是血浆AhR水平的显著因素（分别为[1.61 95%CI 1.08 - 2.38]和[1.84 95%CI 1.22 - 2.77]）。结论 本研究结果可为涉及AhR的胰腺癌诊断提供信息，并为该受体在治疗策略中的潜在疗效提供参考。
